- Home
- CODA vs COEP Comparison
CODA vs COEP Comparison
Compare CODA & COEP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CODA | COEP |
|---|---|---|
| Founded | 1994 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 115.2M | 100.4M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | CODA | COEP |
|---|---|---|
| Price | $10.52 | $14.15 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 160.2K | 54.9K |
| Earning Date | 03-16-2026 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 15.09 | N/A |
| EPS | ★ 0.30 | N/A |
| Revenue | ★ $24,347,217.00 | $500,996.00 |
| Revenue This Year | $30.82 | N/A |
| Revenue Next Year | $20.84 | N/A |
| P/E Ratio | $35.50 | ★ N/A |
| Revenue Growth | ★ 29.34 | N/A |
| 52 Week Low | $5.76 | $6.26 |
| 52 Week High | $12.22 | $21.41 |
Technical Indicators
Market Signals| Indicator | CODA | COEP |
|---|---|---|
| Relative Strength Index (RSI) | 58.07 | 47.23 |
| Support Level | $10.75 | $11.25 |
| Resistance Level | $11.76 | $14.52 |
| Average True Range (ATR) | 0.74 | 1.02 |
| MACD | 0.03 | -0.00 |
| Stochastic Oscillator | 52.90 | 57.35 |
Price Performance
Historical ComparisonAbout CODA Coda Octopus Group Inc.
Coda Octopus Group Inc develops underwater technologies and equipment for imaging, mapping defense, and survey applications. The company's operations are organized into two reportable segments: the Products Segment (Marine Technology Business serving the subsea market and PAL, which sells other products (acoustic hydrophones and acoustic materials to a different market); and the Services Segment (Marine Engineering Business). Its geographical segments are the Americas, Europe, Australia/Asia, and the Middle East/Africa. The majority of revenue is derived from the Products segment.
About COEP Coeptis Therapeutics Holdings Inc.
Coeptis Therapeutics Holdings Inc is a biopharmaceutical company developing cell therapy platforms for patients with cancer. The company's product portfolio consists of multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), a cell therapy technology (CD38-GEAR-NK), and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the company is developing with VyGen-Bio and medical researchers at the Karolinska Institutet.